Current status of the clinical use of PD-1/PD-L1 inhibitors: a questionnaire survey of oncologists in China

Bicheng Zhang(University of Electronic Science and Technology of China), Jun Wang(Shenzhen Bao'an District People's Hospital), Bo Zhu(Huaian First People’s Hospital), Yang Fu(First Affiliated Hospital of Zhengzhou University), Yuxiao Song(Wuhan University), Baocheng Wang(Hong Kong University of Science and Technology)
BMC Cancer
January 31, 2020
10.1186/s12885-020-6583-3
Cited by 23

Related Papers

T-cell exhaustion in the tumor microenvironment
|Cell Death and Disease|2015|1.1k
Clinical characteristics of 82 cases of death from COVID-19
|PLoS ONE|2020|594
Immune Phenotyping Based on the Neutrophil-to-Lymphocyte Ratio and IgG Level Predicts Disease Severity and Outcome for Patients With COVID-19
|Frontiers in Molecular Biosciences|2020|497
Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019
|Clinical Infectious Diseases|2020|458
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417